Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Non-Muscle Invasive Bladder Neoplasms 1Hodgkin Disease 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

Letrozole 20Docetaxel 16Cyclophosphamide 13Zoledronic Acid 12exemestane 11Trastuzumab 11Anastrozole 11Paclitaxel 10Tamoxifen 9Capecitabine 9Fulvestrant 8Epirubicin 8pegfilgrastim 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Saline Solution 6palbociclib 5Sodium Chloride 5Dexmedetomidine 5Carboplatin 5Bupivacaine 5Bevacizumab 5ribociclib 4pegylated granulocyte colony-stimulating factor 4eribulin 4Tranexamic Acid 4Standard of Care 4Pamidronate 4Filgrastim 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Breast Neoplasms × tislelizumab × Clear all
NCT05861635 2023-05-17

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 4 Unknown
42 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡